Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Part of drug trial for patients with atrial fibrillation discontinued

07.09.2005


ACTIVE-A and ACTIVE-I to continue



Study treatments for the ACTIVE W trial of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) program have been discontinued due to a significant difference in efficacy, in favour of the standard oral anticoagulation (OAC) over antiplatelet therapy (clopidogrel plus aspirin).

The ACTIVE trial, the largest randomised international trial program ever conducted in atrial fibrillation (AF), was designed to respond to a largely unmet medical need in the treatment of patients with AF, who are at an increased risk of life-threatening vascular events such as stroke, myocardial infarction and death.


Investigators at 600 sites will adjust their patients’ medications and continue to monitor their health. Approximately 3,000 patients worldwide will be affected by the changes in the study.

After an interim analysis of the study, the recommendation of an independent Data Safety Monitoring Board to discontinue the ACTIVE W trial was endorsed by the ACTIVE study steering committee.

The board also recommended two other trials of the ACTIVE program be continued. The study’s steering committee agreed with the recommendation to discontinue study treatments for ACTIVE W, and endorsed the recommendation to continue the ACTIVE A (clopidogrel compared with ASA alone), and ACTIVE I (irbesartan to placebo in addition to usual blood pressure lowering therapy).

"In the ACTIVE W trial, most of the patients had been receiving OAC prior to entry into the trial," said SalimYusuf, PhD, chairman of the steering committee for the ACTIVE trial program. "These patients achieved high levels of compliance to OAC in the recommended therapeutic range. In the ACTIVE-W trial, a clear benefit in favour of OAC was evident."

Stuart Connolly, MD, principal investigator of the program, emphasized that: "It is important to continue the ACTIVE A and ACTIVE I parts of the study program to evaluate the potential role which clopidogrel can play in the management of atrial fibrillation patients who are intolerant to oral anticoagulants, and to understand the role of irbesartan in patients with atrial fibrillation."

Clinical guidelines recommend the use of OAC therapy for most patients with atrial fibrillation in order to prevent embolic events. However, OAC therapy is associated with a narrow therapeutic window, requires regular monitoring and is contraindicated in some patients. Aspirin is an option in patients who cannot tolerate OACs. The ACTIVE trial programme is designed to evaluate the appropriate place of clopidogrel plus aspirin in the prevention of embolic events in atrial fibrillation patients.

ACTIVE is a phase III multicenter, multinational clinical development program that includes three trials. In ACTIVE A, clopidogrel plus aspirin is compared with aspirin alone in patients who have a contraindication for OACs or are unwilling to take an OAC, with the hypothesis that clopidogrel plus aspirin would be superior to aspirin. ACTIVE I is evaluating whether the angiotensin II receptor antagonist, irbesartan, is superior to placebo (in addition to usual blood pressure lowering therapy) in preventing vascular events in patients with atrial fibrillation.

The ACTIVE trial program is being conducted at more than 600 sites worldwide in 30 countries.

Atrial fibrillation is the most common chronic cardiac rhythm disturbance and it is responsible for a substantial amount of morbidity, disability and mortality in the general population.

Veronica McGuire | EurekAlert!
Further information:
http://www.mcmaster.ca

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>